About Royalty Pharma
Royalty Pharma is a publicly listed company based in New York (United States) founded in 1996 by Rory Riggs and Pablo Legorreta. Investments are made in marketed and late-stage biopharmaceutical companies. The company has 99 employees. Royalty Pharma has completed 4 acquisitions, including Cypress Bioscience, Emgality and Minerva Neurosciences. Its chief executive, as recorded, is Pablo Legorreta. Its website royaltypharma.com draws about 18 thousand monthly visits. Royalty Pharma offers products and services including Royalty Acquisitions and Funding Solutions. Its focus areas include Investment Industry and Private Equity Funds. Its legal entity is Royalty Pharma plc.
Company details
Royalty Pharma was founded in 1996 in New York, United States, and operates as a private equity firm focused on biopharmaceutical investments. Royalties and stakes in marketed and late-stage products are acquired to support development and commercialization. In 2022, annual revenues of 2.24 billion were achieved, with net profit at 0.04 billion. Operations span global biopharma sectors, led by executives including co-founders Pablo Legorreta and Rory Riggs.
- Headquarters New York, United States
- Employees 99
- Founders Rory Riggs, Pablo Legorreta
- Stage Public
- SectorsFinancial Services
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website royaltypharma.com
- Social LinkedIn
- Legal Name Royalty Pharma Plc
- Annual Revenue$2.38 B (USD)5.06as on Dec 31, 2025
- Net Profit$770.95 M (USD)-10.25as on Dec 31, 2025
- EBITDA$1.56 B (USD)20.96as on Dec 31, 2025
- Investors
- Employee Count99
- Investments & AcquisitionsCypress Bioscience
& 3 more
Products & Services of Royalty Pharma
Royalty Pharma offers a comprehensive portfolio of products and services, including Royalty Acquisitions and Funding Solutions.
Biopharmaceutical royalties are acquired by Royalty Pharma to support funding in life sciences
Tailored funding solutions are provided by Royalty Pharma for innovation in biotechnology and pharmaceuticals
Funding Insights of Royalty Pharma
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Royalty Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2020 | Private Equity Round | – | – |
1 investors in total: 1 institutional.
Investors in Royalty Pharma
Royalty Pharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include General Atlantic.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity fund focused on global markets | 1980 | generalatlantic.com | New York, United States |
Investor details for Royalty Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Royalty Pharma
54 people are tracked at Royalty Pharma (26 in leadership, 7 in board & advisors, 21 in team); the tracked headcount is 99.
| Name | Role | Group |
|---|---|---|
Rory Riggs | Co-Founder | Leadership |
Pablo Legorreta | Co-Founder & Chief Executive Officer | Leadership |
Christopher Hite | Vice Chairman | Leadership |
Jim Reddoch | Executive Vice President | Leadership |
George Lloyd | Executive Vice President | Leadership |
Terrance Coyne | CFO | Leadership |
George Grofik | Head of Investor Relations & Communications | Leadership |
Bill Grau | Vice President | Leadership |
Mina F. | Tax Director | Leadership |
Stephanie Ratner | Director Of Statutory Accounting | Leadership |
Sam Landsberg | Senior Vice President, Finance And Treasurer | Leadership |
Matthew Lyons | Vice President | Leadership |
Brienne Kugler | VP, Research & Investments | Leadership |
Molly Sawaya | Evp, Head Of Human Capital | Leadership |
Carrie Goodman | Director Of Family Office | Leadership |
Ashwin Pai | Executive Vice President, Investments | Leadership |
Sara Klymkowsky | VP, Research & Investments | Leadership |
Yu-Chun Lin | VP, External Reporting & SOX Compliance | Leadership |
Kristin Stafford | Chief Accounting Officer | Leadership |
Jae Ro | Chief Information Security Officer | Leadership |
34 more people are available in the full profile.
Complete people profiles for Royalty Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Royalty Pharma
Royalty Pharma is a publicly listed company on the NASDAQ with ticker symbol RPRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jun 2020
- Listed onNASDAQ: RPRX
- Listed entityRoyalty Pharma plc
- Exchange sectorHealth technology
- ISINGB00BMVP7Y09
- Share price$56.57 (-2.09% on the day) · 2026-10-13
- Market capitalisation$32.53B
- Price to earnings30.1
- EPS (diluted, trailing year)$1.88
- Dividend yield1.6%
- Volume (last session)3,582,477
Financials of Royalty Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $2.38B | $771.0M | $1.56B |
| 2024 | $2.26B | $859.0M | $1.29B |
| 2023 | $2.35B | $1.13B | $1.49B |
| 2022 | $2.24B | $42.8M | $928.6M |
| 2021 | $2.29B | $619.7M | $1.45B |
Detailed financial statements for Royalty Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Royalty Pharma
Royalty Pharma has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Cypress Bioscience, Emgality and Minerva Neurosciences.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developing drugs against Psychiatric and other CNS Diseases | minervaneurosciences.com | Waltham, United States | 2007 | Jan 2021 | $60M | |
Therapeutics for rare and ultra-rare metabolic diseases are developed. | ultragenyx.com | Novato, United States | 2010 | Dec 2019 | $320M | |
Patient healthcare services are provided to support individual well-being. | emgality.com | Indianapolis, United States | 2016 | Apr 2019 | $260M | |
Drugs for patients suffering from a variety of disorders of the central nervous system | cypressbio.com | San Diego, United States | 1981 | Dec 2010 | $255M |
Complete acquisition details for Royalty Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Royalty Pharma
7 dated milestones of Royalty Pharma across 25 years, from founding to its latest funding, stage changes and deals.
- Founded Royalty Pharma is founded.
- Acquisition Acquires Cypress Bioscience.
- Acquisition Acquires Emgality.
- Acquisition Acquires Ultragenyx.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Minerva Neurosciences.
Web traffic of Royalty Pharma
The website of Royalty Pharma (royaltypharma.com) receives about 17.6K visits a month and ranks #1,488,529 among all websites worldwide, #1,959 in Biotechnology and Pharmaceuticals.
- Monthly visits17.6K
▲ 34.7% vs previous month
- Unique visitors5.5K
per month
- Global rank#1,488,529
among all websites
- Category rank#1,959
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit3.3
- Average visit3 min 34 sec
- DevicesDesktop 49% · Mobile 51%
Websites whose visitors overlap most with Royalty Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| baybridgebio.com | 100% | #2,427,497 | View details | ||
news.vrtx.com | news.vrtx.com | 98% | #1,559,216 | – | |
| nektar.com | 86% | 19.6K | #959,308 | View details | |
| ifpma.org | 85% | #875,178 | View details | ||
| biopharmadive.com | 85% | 680.7K | #208,628 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Royalty Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Private Equity Funds
3 companies that operate in the same segment as Royalty Pharma (Private Equity Funds) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Alternative asset investment management firm | 1997 | Los Angeles, California, United States | USD 6.2 B | 3,200 | ||
Private equity and debt investments are managed for businesses. | 2004 | Los Angeles, California, United States | USD 3.15 B | 3,200 | ||
Multiple sectors are invested in by this private equity firm. | 1976 | New York, New York, United States | USD 20.29 B | 4,830 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Royalty Pharma
Complete news archive for Royalty Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Royalty Pharma
Royalty Pharma was founded in 1996 and raised its 1st funding round 24 years after it was founded.
Royalty Pharma is headquartered in New York, United States. It is registered at New York, New York, United States.
Pablo Legorreta is the CEO of Royalty Pharma, as recorded in our data. They have also founded this company.
Royalty Pharma has 99 employees.
Annual revenue of Royalty Pharma is $2.38B as on Dec 31, 2025.
Royalty Pharma was founded in 1996 in New York, United States, and operates as a private equity firm focused on biopharmaceutical investments. Royalties and stakes in marketed and late-stage products are acquired to support development and commercialization. In 2022, annual revenues of 2.24 billion were achieved, with net profit at 0.04 billion. Operations span global biopharma sectors, led by executives including co-founders Pablo Legorreta and Rory Riggs.
Royalty Pharma offers Royalty Acquisitions and Funding Solutions.
Yes, Royalty Pharma is publicly traded on NASDAQ under the ticker symbol RPRX.
Royalty Pharma has made 4 acquisitions, including Cypress Bioscience, Emgality, and Minerva Neurosciences.
Royalty Pharma has 1 investor. Key investors include General Atlantic.
Royalty Pharma operates through Royalty Pharma Plc.